Pharma BD Deal Intelligence
A bargain that paid off: Bayer's $800M radium-223 pact with Algeta — called 'extremely positive' and larger than analysts expected — delivered Xofigo's FDA accelerated approval and EU authorization, validating the bet before Bayer folded Algeta in outright for $2.9B in 2014.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →'The Alpharadin deal with Bayer totals up to $800 million (EUR560m) to Algeta.' 'In Bayer we have selected a world-class oncology company with a proven global…
Algeta and Bayer signed a 2009 development and commercialization agreement valued at $800M for Xofigo globally; Bayer fully acquired Algeta for $2.9B in March…
Xofigo's EU marketing authorization for CRPC patients with symptomatic bone metastases positions it as a unique bone-targeted alpha-radiotherapy with a…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Co-development/commercialization of radium-223 (Xofigo) for CRPC bone mets. ~$800M deal value. Source: Bayer/Algeta press, Norway business publications.
299K US cases/yr
mCRPC is advanced prostate cancer that progresses despite androgen-deprivation therapy. Bone is the dominant metastatic site, and skeletal-related events (fractures, cord compression, pain) drive much of the morbidity and mortality. Treatment historically focused on palliation until life-prolonging therapies emerged in the early 2010s.
When Bayer signed the Algeta deal in September 2009, the mCRPC armamentarium was limited to docetaxel (Taxotere, Sanofi) for chemotherapy-eligible patients. Between 2010-2013, the landscape transformed with sipuleucel-T (Provenge, Dendreon, 2010), cabazitaxel (Jevtana, Sanofi, 2010), abiraterone (Zytiga, J&J, 2011), enzalutamide (Xtandi, Astellas/Pfizer, 2012), and finally radium-223 (Xofigo, May 2013) — six life-prolonging agents now anchor NCCN/AUA/ASCO guidelines. Xofigo's differentiation is mechanistic: it is the first alpha-particle emitter approved for any cancer, mimicking calcium to deposit short-range cytotoxic radiation directly in bone-mets microenvironments, with a 14.0 vs 11.2-month median OS benefit in ALSYMPCA. The Bayer-Algeta deal gave Bayer a non-overlapping bone-targeted modality alongside Nexavar/Stivarga, and positioned the company in nuclear oncology a decade ahead of the radiopharmaceutical resurgence (Lu-177-PSMA, Pluvicto). Bayer fully acquired Algeta for $2.9B in March 2014 once the strategic value crystallized post-FDA approval.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Algeta ASA (this deal) | 2009 | $800M | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2009 deals · Bayer AG deals